1. Home
  2. DJT vs MPLT Comparison

DJT vs MPLT Comparison

Compare DJT & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trump Media & Technology Group Corp.

DJT

Trump Media & Technology Group Corp.

N/A

Current Price

$9.06

Market Cap

2.1B

Sector

Technology

ML Signal

N/A

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$10.81

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DJT
MPLT
Founded
2021
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.7B
IPO Year
2021
2025

Fundamental Metrics

Financial Performance
Metric
DJT
MPLT
Price
$9.06
$10.81
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $32.67
AVG Volume (30 Days)
★ 2.9M
504.0K
Earning Date
05-08-2026
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 82.39
EPS
★ N/A
N/A
Revenue
★ $3,682,600.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 1.76
N/A
52 Week Low
$6.96
$9.10
52 Week High
$17.97
$40.43

Technical Indicators

Market Signals
Indicator
DJT
MPLT
Relative Strength Index (RSI) N/A 31.34
Support Level N/A $10.67
Resistance Level N/A $20.20
Average True Range (ATR) 0.00 0.79
MACD 0.00 0.08
Stochastic Oscillator 0.00 16.14

Price Performance

Historical Comparison
DJT
MPLT

About DJT Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp is a media and technology company rooted in social media, digital streaming, information technology infrastructure, and more. Its initial product launch will focus on its social media platform, Truth Social, which encourages an open, free, and honest conversation without discriminating against political ideology.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: